China

The Gavi-China partnership dates to 2002 when Gavi supported China on the introduction of the hepatitis B vaccine. This catalytic factor led to the government including the vaccine into its Expanded Programme for Immunization.

Since the start of the project, the percentage of newborn children immunised with the first dose at birth has climbed from 64% to more than 90% in most areas. As a result, less than 1% of children under five are now chronic carriers of hepB.

China became a donor to Gavi at the Berlin Pledging Conference 2015 with an initial contribution of US$ 5 million for the 2016–2020 period.

China’s transformation from a recipient of Gavi support to an important donor exemplifies the ideal trajectory for countries to participate and contribute to global health advancement, underscoring the long-term vision of the Gavi model.

At the Global Vaccine Summit on 4 June 2020, China pledged a US$ 20 million new contribution to support Gavi’s work for the 2021–2025 strategic period, recognising the important work of the Alliance in providing life-saving vaccines to children around the world.